Immunic reports new, positive long-term open-label extension data from phase 2 emphasis trial of vidofludimus calcium in relapsing-remitting multiple sclerosis

– at week 144, 92.3% of patients remained free of 12-week confirmed disability worsening (cdw) with 92.7% remaining free of 24-week cdw – – vidofludimus calcium continues to demonstrate favorable safety and tolerability profile; long-term data now available up to 5.5 years – new york , june 24, 2025 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today reported new long-term open-label extension (ole) data from its phase 2 emphasis trial of lead asset, orally available nuclear receptor-related 1 (nurr1) activator, vidofludimus calcium (imu-838), in patients with relapsing-remitting multiple sclerosis (rrms). "it is meaningful to see that patients treated with vidofludimus calcium during the ole period of our phase 2 emphasis trial in rrms experienced a low rate of confirmed disability worsening (cdw) events, as measured by the expanded disability status scale (edss).
IMUX Ratings Summary
IMUX Quant Ranking